PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases
Open Access
- 1 December 2014
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 93 (28), e326
- https://doi.org/10.1097/md.0000000000000326
Abstract
Vedolizumab is an anti-inflammatory monoclonal antibody that exclusively targets the alpha 4 beta 7 integrin. We aimed to systematically review the efficacy and safety of vedolizumab for patients with inflammatory bowel diseases (IBDs). PubMed, EMBASE, and the Cochrane Library were searched up to May 2014. Randomized controlled trials examining the efficacy or safety of vedolizumab in patients with IBDs were eligible for inclusion. Data were extracted independently by 2 investigators and pooled using Review Manager 5.0 software (The Cochrane Collaboration, Copenhagen). Results were expressed as the relative risk (RR) with 95% confidence intervals (CIs). Six randomized controlled trials involving 2815 patients were eligible for inclusion. Vedolizumab was more effective than placebo for patients with ulcerative colitis and Crohn disease (CD) in clinical response (RR = 1.82, 95% CI, [1.43, 2.31]; RR = 1.46, 95% CI [1.18,1.81]) and clinical remission (RR = 2.23, 95% CI [1.35, 3.68]; RR = 1.71, 95% CI [1.25, 2.34]) during induction therapy. A superior effect was found during maintenance therapy in durable clinical/CD Activity Index-100 response (RR = 2.22, 95% CI [1.62, 3.05]; RR = 1.48, 95% CI [1.13, 1.94]) and clinical remission (RR = 2.55, 95% CI [1.38, 4.70]; RR = 1.15, 95% CI [0.75, 1.77]). However, vedolizumab may be associated with serious adverse events (RR = 1.25, 95% CI [1.03, 1.52]) and nasopharyngitis (RR = 1.56, 95% CI [1.08, 2.25]) for patients with CD. Vedolizumab was more effective than placebo as induction and maintenance therapy for IBDs, with an acceptable short-term safety profile, and achieving cure, although it may be associated with serious adverse events and nasopharyngitis for patients with CD.This publication has 39 references indexed in Scilit:
- Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel diseaseJournal of Crohn's and Colitis, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2013
- New and emerging treatments for ulcerative colitis: a focus on vedolizumabBiologics: Targets and Therapy, 2013
- Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease – an updateExpert Review of Clinical Immunology, 2013
- Vedolizumab for the treatment of ulcerative colitis and Crohn’s diseaseImmunotherapy, 2012
- Review article: loss of response to anti-TNF treatments in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2011
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7Integrin Therapeutic Antibody in Development for Inflammatory Bowel DiseasesJournal of Pharmacology and Experimental Therapeutics, 2009
- Natalizumab for induction of remission in Crohn's diseaseCochrane Database of Systematic Reviews, 2007
- Treatment of Ulcerative Colitis with a Humanized Antibody to the α4β7IntegrinNew England Journal of Medicine, 2005
- Corticosteroids in Crohn's diseaseThe American Journal of Gastroenterology, 2002